Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | NMBR | P28336 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7439119 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BSYKPPARAACE | |
| SCHEMBL30343682 | 1.00 | ITGB3 (0.45) | ITGB3ITGA2BSYKPPARAACE | |
| SCHEMBL25240561 | 0.94 | TACR1 (0.47) | SYKNMBRCTSKCTSLCTSB | |
| SCHEMBL19340443 | 0.94 | TACR1 (0.47) | SYKNMBRCTSKCTSLCTSB | |
| SCHEMBL30002314 | 0.94 | TACR1 (0.47) | SYKNMBRCTSKCTSLCTSB | |
| SCHEMBL16100108 | 0.90 | CTSS (0.48) | PPARAACECTSKCTSLCTSS | |
| SCHEMBL31407630 | 0.90 | CTSS (0.48) | PPARAACECTSKCTSLCTSS | |
| SCHEMBL16100109 | 0.90 | CTSS (0.48) | PPARAACECTSKCTSLCTSS | |
| SCHEMBL19410161 | 0.89 | PLA2G2A (0.47) | ITGB3ITGA2BPPARAACE | |
| SCHEMBL19410159 | 0.89 | PLA2G2A (0.47) | ITGB3ITGA2BPPARAACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199701-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-20 | — | — | US | disclosed |
| CN-118159549-A | Immunomodulators | 百时美施贵宝公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118076623-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117940445-A | Macrocyclic immunomodulators | 百时美施贵宝公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4314012-A1 | IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-110997698-B | Immunomodulatory agents acting as PD-1 antagonists | 百时美施贵宝公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-117157306-A | Immunomodulators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-110997698-A | Immunomodulators acting as PD-1 antagonists | 百时美施贵宝公司 | 2020-04-10 | — | — | CN | disclosed |
| EP-3191113-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10358463-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-23 | — | — | US | disclosed |
| EP-3440097-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | Bristol-Myers Squibb Company (US) | 2019-02-13 | — | — | EP | disclosed |
| WO-2018237153-A1 | IMMUNOMODULATORS ACTING AS ANTAGONISTS OF PD-1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-27 | — | — | WO | disclosed |
| WO-2017176608-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170283463-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
| US-20170260237-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-14 | — | — | US | disclosed |
| EP-3191113-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-LI PROTEIN/PROTEIN INTERACTIONS | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016039749-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-LI PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199701-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | ITGB3 3764/4885ITGA2B 3218/4885SYK 1269/4885 |
| US-20170283463-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | ITGB3 3764/4885ITGA2B 3218/4885SYK 1269/4885 |
| US-10358463-B2 | Immunomodulators | CD274, PDCD1, PDCD1LG2 | ITGB3 3764/4885ITGA2B 3218/4885SYK 1269/4885 |
| US-20170260237-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | ITGB3 3066/4885ITGA2B 2698/4885SYK 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.